TL;DR
Vara, a Berlin company whose software already runs across more than half of Germany’s organised breast screening, has been certified under the EU medical device rules to report clearly normal mammograms as normal without a radiologist looking at them. It is the first clearance of its kind for breast AI anywhere. Anything the model does not clear still goes to a human as before.
Autonomous means something specific here
The distinction that matters is between assisting and acting. Screening AI has been decision support for years — flagging regions, prioritising worklists, offering a second opinion. This certification removes the human from one branch of the pathway entirely, and only that branch. The rationale is workforce arithmetic: population programmes that read every mammogram twice are running short of radiologists to do it.
What made the regulator comfortable is not the classifier but the supervision wrapped around it. Vara’s monitoring layer, ATMON, sets an operating threshold per site and watches it continuously, tracking equipment changes, system health and daily performance signals. If those drift beyond defined bounds the site reverts to full human reading automatically. The company positions this as the ongoing oversight the EU AI Act will demand of high-risk deployments — regulatory design as a product feature.
The evidence base is genuine. Vara’s PRAIM study, in Nature Medicine last year, followed 461,818 women through a national programme with nobody excluded, making it the largest prospective trial of AI screening conducted so far.
Read with the sourcing in mind
This came through a press wire, so the framing is the company’s own and the claim of a world first is theirs rather than a notified body’s. The underlying certification is verifiable; the superlative is marketing.
Looking forward
A CE mark does not open the British market — Great Britain has its own route through the MHRA, and NHS breast screening runs on double reading by design, so adopting this would mean changing a programme protocol rather than buying a product. But the precedent is what travels. Recent months have brought AI reading heart disease from mammograms and heart failure from a standard ECG; this is the first time a regulator has let one of these systems close a case unsupervised. Every screening programme in Europe now has a worked example to argue about.